Alnylam Pharmaceuticals’ (ALNY) “Buy” Rating Reaffirmed at HC Wainwright

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $510.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 53.47% from the stock’s current price.

Other equities analysts have also issued reports about the stock. Royal Bank Of Canada dropped their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research report on Tuesday, January 20th. Piper Sandler reissued an “overweight” rating and set a $489.00 price target (up from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Leerink Partners lowered their price objective on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research report on Monday, December 15th. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Finally, Oppenheimer assumed coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price target on the stock. Twenty-two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $477.96.

Alnylam Pharmaceuticals Stock Performance

ALNY traded down $0.30 during trading on Wednesday, hitting $332.32. The company’s stock had a trading volume of 461,230 shares, compared to its average volume of 1,595,379. The business’s 50 day simple moving average is $371.01 and its 200-day simple moving average is $424.25. The firm has a market cap of $43.90 billion, a PE ratio of 194.34 and a beta of 0.35. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter last year, the firm posted ($0.65) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 84.9% on a year-over-year basis. As a group, sell-side analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 2,242 shares of the stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the sale, the executive vice president owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. This represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Tolga Tanguler sold 1,959 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $607,446.72. Following the completion of the sale, the executive vice president owned 31,769 shares of the company’s stock, valued at $9,850,931.52. This trade represents a 5.81% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 36,578 shares of company stock worth $12,416,105. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ALNY. Man Group plc lifted its stake in shares of Alnylam Pharmaceuticals by 101.2% during the 4th quarter. Man Group plc now owns 144,210 shares of the biopharmaceutical company’s stock worth $57,345,000 after purchasing an additional 72,537 shares during the last quarter. Hunting Hill Global Capital LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $1,694,000. Janus Henderson Group PLC boosted its holdings in shares of Alnylam Pharmaceuticals by 0.4% in the 4th quarter. Janus Henderson Group PLC now owns 136,425 shares of the biopharmaceutical company’s stock valued at $54,252,000 after acquiring an additional 570 shares during the last quarter. Gotham Asset Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 40.8% during the 4th quarter. Gotham Asset Management LLC now owns 39,622 shares of the biopharmaceutical company’s stock valued at $15,756,000 after buying an additional 11,487 shares during the last quarter. Finally, Evolve Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $709,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $429 and maintained a Buy rating, signaling meaningful upside vs. the current price and supporting bullish investor expectations. Read More.
• Positive Sentiment: Freedom Capital Markets published an upgrade on ALNY, adding to the recent analyst-driven optimism that helped push the stock higher. Read More.
• Positive Sentiment: A pundit upgrade covered by The Motley Fool increased retail/informed interest and trading activity, contributing to recent upside momentum. Read More.
• Positive Sentiment: Large institutional buying reported for Q4 (notably AQR, Guggenheim, Caisse de dépôt, Schonfeld) indicates strong professional investor interest and supports longer‑term demand. Read More.
• Neutral Sentiment: Recent short-interest figures in feeds show zero/NaN values and a 0.0 days-to-cover — likely a reporting/data artifact rather than new market pressure; treat as non-actionable until exchange-confirmed. Read More.
• Neutral Sentiment: Alnylam reported quarterly results on Feb. 12 that showed strong revenue growth but an EPS miss (reported $0.82 vs. $1.43 expected); that earnings miss still weighs on near-term expectations and valuation multiples. Read More.
• Negative Sentiment: Multiple insider sales were disclosed this week: CEO Yvonne Greenstreet sold 6,958 shares (~$310 avg) and several EVPs sold mid‑thousands of shares around the $310–332 range, each reducing ownership by mid‑single-digit percentages — these coordinated sales can sap sentiment despite routine liquidity/compensation explanations. Read More. Read More.
• Negative Sentiment: EVP Kevin J. Fitzgerald recently disclosed multiple share sales (1,959 shares on Feb. 13 at ~$310 and additional sales on Feb. 17), trimming his stake — individual executive sales add to the week’s negative optics. Read More.
• Negative Sentiment: Chardan trimmed its price target slightly (to $425), a modest counterpoint to other upgrades that tempers upside expectations. Read More.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.